Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system

Stroke

Volumn 41, Issue 7, 2010, Pages 1459-1463

  Robinson, Maisha T ^a   Rabinstein, Alejandro A ^a   Meschia, James F ^b   Freeman, William D ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

Factor VII; intracranial hemorrhage; safety; warfarin

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BRAIN HEMORRHAGE; CENTRAL NERVOUS SYSTEM; DEEP VEIN THROMBOSIS; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VALVE PROSTHESIS; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STROKE; SUBDURAL HEMATOMA; THROMBOEMBOLISM; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; MIDDLE AGED; SPINAL HEMATOMA;

ADULT; AGED; AGED, 80 AND OVER; CENTRAL NERVOUS SYSTEM DISEASES; CEREBRAL HEMORRHAGE; FACTOR VIIA; FEMALE; HEMATOMA, EPIDURAL, SPINAL; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; WARFARIN;

EID: 77954175707     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.581538     Document Type: Article

References (32)

1. Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, Begtrup K, Steiner T. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66: 1175-1181.
2. Zubkov AY, Mandrekar JN, Claassen DO, Manno EM, Wijdicks EF, Rabinstein AA. Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol. 2008;65:1320-1325.
3. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63:1059-1064.
4. Hart RG. What causes intracerebral hemorrhage during warfarin therapy? Neurology. 2000;55:907-908.
5. Mayer SA. Intracerebral hemorrhage: natural history and rationale of ultra-early hemostatic therapy. Intensive Care Med. 2002;28(suppl 2):S235-240.
6. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(suppl):160S-198S.
7. Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, Smith EE, Greenberg SM, Rosand J. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006;37:151-155.
8. Hemphill JC III. Treating warfarin-related intracerebral hemorrhage: is fresh frozen plasma enough? Stroke. 2006;37:6-7.
9. Manno EM, Atkinson JL, Fulgham JR, Wijdicks EF. Emerging medical and surgical management strategies in the evaluation and treatment of intracerebral hemorrhage. Mayo Clin Proc. 2005;80:420-433.
10. Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology. 2006;67:1272-1274.
11. Freeman WD, Brott TG, Barrett KM, Castillo PR, Deen HG Jr, Czervionke LF, Meschia JF. Recombinant factor VIIia for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc. 2004;79:1495-1500.
12. Ilyas C, Beyer GM, Dutton RP, Scalea TM, Hess JR. Recombinant factor VIIa for warfarin-associated intracranial bleeding. J Clin Anesth. 2008; 20:276-279.
13. Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg. 2003;98:737-740.
14. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med Sci Monit. 2002;8:CS98-100.
15. Sørensen B, Johansen P, Nielsen GL, Sørensen JC, Ingerslev J. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thrombopro-phylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis. 2003;14:469-477.
16. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anti-coagulation with recombinant human factor VIIa concentrate. Ann Intern Med. 2002;137:884-888.
17. Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, Broderick JP. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke. 2008;39: 850-856.
18. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Recombinant activated factor vii for acute intra-cerebral hemorrhage. N Engl J Med. 2005;352:777-785.
19. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358: 2127-2137.
20. Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recom-binant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care. 2005;2:263-267.
21. Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of anticoagulant- associated intracerebral hemorrhage. Neurology. 2007;68: 116-121.
22. Flaherty ML, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, Khatri P, Stettler B, Adeoye O, Moomaw CJ, Broderick JP, Woo D. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008; 71:1084-1089.
23. Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, Broderick JP. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke. 2010;41: 48-53.
24. Orken DN, Kenangil G, Ozkurt H, Guner C, Gundogdu L, Basak M, Forta H. Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage. Neurologist. 2009;15: 329-331.
25. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83:137-143.
26. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Beriplex P/N Anticoagulation Reversal Study Group. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622-1231
27. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res. 2007;121:9-16.
28. Kessler CM. Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data? J Thromb Haemost. 2006;4:963-966.
29. Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg. 2000;14:458-461.
30. Fredriksson K, Norrving B, Strömblad LG. Emergency reversal of anti-coagulation after intracerebral hemorrhage. Stroke. 1992;23:972-977.
31. Ogata T, Yasaka M, Wakugawa Y, Inoue T, Ibayashi S, Okada Y. Deep venous thrombosis after acute intracerebral hemorrhage. J Neurol Sci. 2008;272:83-86.
32. Lacut K, Bressollette L, Le Gal G, Etienne E, De Tinteniac A, Renault A, Rouhart F, Besson G, Garcia JF, Mottier D, Oger E. VICTORIAh (Venous Intermittent Compression and Thrombosis Occurrence Related to Intra-cerebral Acute hemorrhage)Investigators. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. Neurology. 2005;65:865-869. (Pubitemid 41362131)